Disitamab vedotin

Disitamab vedotin
Clinical data
Trade names	Aidixi
Legal status
Legal status	Rx in China;
Identifiers
CAS Number	2136633-23-1;
PubChem SID	472420323;
UNII	RB3U3A1S27;
ChEMBL	ChEMBL5095273;

Disitamab vedotin (trade name Aidixi) is a drug for the treatment of various types of solid tumors.^[1] It is an antibody-drug conjugate that consists of an immunoglobulin G1 antibody that is linked to the antitumor agent vedotin (monomethyl auristatin E).

^ Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M (December 2022). "Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy". Drug Delivery. 29 (1): 1335–1344. doi:10.1080/10717544.2022.2069883. PMC 9090390. PMID 35506447.

[1] Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M (December 2022). "Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy". Drug Delivery. 29 (1): 1335–1344. doi:10.1080/10717544.2022.2069883. PMC 9090390. PMID 35506447.

[1]